Proteinkinase Inhibitors (eBook, PDF)

Redaktion: Laufer, Stefan

• Format: PDF

Produktbeschreibung

Overview chapters introduce the newcomer to the topic covered

Series covers hot topics of frontier research summarized by reputed scientists in the field

Volumes are useful and of relevance for a long period of time

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer Nature Switzerland
• Seitenzahl: 256
• Erscheinungstermin: 23. März 2021
• Englisch
• ISBN-13: 9783030681807
• Artikelnr.: 61358077

Autorenporträt

Stefan Laufer is a Professor of Pharmaceutical/Medicinal Chemistry at Tuebingen University, Germany, and he had previously worked for 10 years in the Pharmaceutical Industry. His research interests are anti-inflammatory and cancer drug discovery with various eicosanoid (COX-1,2,3, LOXs, mPGES1, cPLA2) and protein kinase targets (p38, JAKs, JNKs, CK1d, mtEGRFs). Three compounds from his lab entered clinical development phases. Dr. Laufer chairs the ICEPHA (Interfaculty Center for Pharmacogenomics and Drug Research) and TüCADD, Tuebingen Center for Academic Drug Discovery. As part of this work, a proprietary kinase inhibitor collection is established (TüKIC, 10.000 cpds). He authored more than 500 publications, 14 books/bookchapters, and is inventor in 42 patent families.

Inhaltsangabe

ProteinKinase-Inhibitors: A Story of Success.- Function, Structure and Topology of Proteinkinases.- Molecular Modelling.- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR.- Achieving high level of selectivity for kinase inhibitors.- Inhibitors of c-Jun N-terminal kinase 3.- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook.- Covalent Janus Kinase 3 Inhibitors.